Glioblastoma (GBM) is the most lethal brain tumor, with a median survival rate of merely 12-16 months after diagnosis.

and is being evaluated in clinical trials today -- targets immune cells known as macrophages and their brain-resident versions, microglia, both of which are manipulated by GBM cells to support ...

Volume 2 Issue 9封面解读刘鹏胡亚伟Diffuse midline glioma (DMG), H3K27-altered, is a lethal pediatric high-grade tumor, lacking ...

Joyce and colleagues reported on their studies in Cancer Cell, in a paper titled “Fibrotic response to anti-CSF-1R therapy potentiates glioblastoma recurrence.” GBM is the most common and ...

【导读】感染单纯疱疹病毒1（HSV-1）后，该病毒会部署多种策略，来逃避宿主的先天免疫反应。然而，控制这种现象的机制仍然难以捉摸。在这项研究中，团队发现HSV-1通过在神经胶质瘤细胞的早期感染期间选择性地减少METTL14蛋白，导致总体m6A水平降低 ...

Name: Sarah Gao Class Year: 2025 Major: Biochemistry and Molecular Biology Hometown: Beijing, China Internship Organization: ...

Researchers have developed a promising CAR-T cell therapy targeting glioblastoma, the most aggressive brain tumor.

Richard Lounsbery Award recipient, will present the 2024 Lounsbery Lecture on "Neuron-glial Interactions in Health and ...

Genenta Science (NASDAQ: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, is pleased to announce that the Agenzia Italiana del Farmaco (AIFA) has approved a new Phase 1 ...

H3K27-altered, is a lethal pediatric high-grade tumor, lacking effective treatment options, primarily depending on clinical trials. Epigenetic agent-based immunotherapy has shown promise, but the ...